The company develops, produces and markets nanotechnologies for the life sciences. They produce a variety of nano-structured surfaces for use in research and are also developing a range of products that derive from a proprietary platform technology using liquid crystals for the rapid detection of molecular interactions.
PolyRemedy, Inc. manufactures robotic systems for the fabrication of nano-material based wound dressings at the point-of-care, allowing wound care clinicians to deliver easily and cost-effectively customized wound care on-demand for each patient's unique wound.
Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research.
Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), are jointly pursuing the development of water-soluble nano-polymers for targeted delivery of anticancer drugs.
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.
Senova Systems owns an exclusive worldwide license from Oxford University for a breakthrough pH sensor that does not require calibration, is not subject to fouling, and does not drift with changes in temperature. The company is developing these revolutionary new pH Meters to meet specific needs in all process industries.
Develops, manufactures, and sells a broad range of biological based materials and services essential for the manufacture of diagnostic tests, commercial bioproduction of therapeutic drugs,including clinically annotated DNA and RNA.
Sirnaomics, Inc. is dedicated to becoming the leader in the RNAi technology focusing on (1) enhancement of the potency of active pharmaceutical ingredient (API) using multi-targeted small interfering RNA (siRNA) cocktail; (2) improvement of the API delivery in vivo using clinical viable synthetic polymeric and lipid nanoparticles.